$739 Million Acquisition of XOMA Strengthens Ligand’s Biopharma Portfolio

Ligand Pharmaceuticals has agreed to acquire XOMA Royalty in a transaction valued at approximately $739 million, reflecting continued consolidation in the biopharmaceutical royalty financing space. The deal is expected to significantly expand Ligand’s portfolio of royalty-generating assets and underscores the growing role of alternative funding models in drug development, according to an April 27, 2026 announcement.¹

Royalty aggregators have emerged as a distinct segment within the biopharmaceutical ecosystem, providing non-dilutive capital to companies in exchange for future revenue streams tied to therapeutic products. This model has gained traction as developers seek to fund late-stage clinical programs while managing financial risk.²

How does the XOMA Royalty acquisition expand Ligand’s portfolio strategy?

The acquisition will add more than 120 assets across commercial, clinical, and preclinical stages to Ligand’s existing portfolio, bringing its total to more than 200 assets. Among these are seven marketed products, including Roche’s faricimab-svoa (Vabysmo), Day One Pharmaceuticals’ tovorafenib (Ojemda), and Zevra Therapeutics’ arimoclomol (Miplyffa), as well as a number of late-stage development programs.

The expanded portfolio spans multiple therapeutic areas, including oncology, ophthalmology, central nervous system disorders, and rare diseases. Diversification across both modalities and development stages may help Ligand mitigate risk associated with individual asset performance while supporting more stable long-term revenue streams, according to the company.

"The acquisition of XOMA Royalty presents a compelling opportunity for us to strengthen and diversify our portfolio across all stages of clinical development and accelerate our long-term profitable growth," said Todd Davis, CEO of Ligand, in a company press release.¹

What does this deal signal about the evolution of biopharma financing models?

The transaction highlights a broader movement toward alternative financing structures within the biopharmaceutical industry. Royalty-based funding allows companies to monetize future product revenues without issuing equity or incurring traditional debt, which can be particularly attractive for firms advancing high-cost clinical programs.³

By acquiring XOMA Royalty, Ligand nearly doubles its portfolio of phase 2 and phase 3 assets, potentially increasing exposure to near-term clinical and regulatory milestones. This concentration in later-stage programs may enhance the predictability of future royalty flows, although outcomes remain dependent on clinical success and regulatory approvals.^2,3

“After evaluating a broad range of strategic and financing alternatives, we believe combining our diverse portfolio with a company that shares our commitment to helping the biopharmaceutical industry thrive represents the most compelling outcome for XOMA Royalty’s stockholders,” said Owen Hughes, CEO of XOMA Royalty, in the release.¹

The deal structure includes contingent value rights, which may provide additional returns to XOMA shareholders depending on the outcome of ongoing litigation with Janssen Biotech related to guselkumab (Tremfya).¹ Such mechanisms are increasingly used in biopharma transactions to account for uncertain future events, including legal or regulatory outcomes.⁴

How might expanded royalty platforms influence drug development pipelines?

The growth of royalty aggregators may play a role in sustaining innovation by providing flexible capital to smaller biotechnology companies. By monetizing future revenue streams, developers can reinvest in pipeline advancement, potentially accelerating timelines for bringing new therapies to market.²

Ligand also raised its 2026 financial guidance in connection with the transaction, citing expectations that the acquisition will be immediately accretive to adjusted earnings per share.¹ While financial metrics are not the primary driver of clinical innovation, access to capital remains a key enabler of drug development activity.³

From a strategic perspective, the combined portfolio may position Ligand to capture value across a wide range of therapeutic programs, including those targeting unmet medical needs. However, as with other royalty-based models, the long-term impact will depend on the success of underlying assets and the ability to effectively manage a large and diverse portfolio.^1,2

The transaction, expected to close in the third quarter of 2026 pending approvals, reflects continued maturation of the royalty aggregation model within biopharma. As companies explore new ways to finance innovation, such deals may shape how capital is deployed across the drug development landscape, potentially influencing both pipeline progression and patient access to emerging therapies.^1,3

References

1. Ligand Pharmaceuticals. Ligand to acquire XOMA Royalty, further accelerating profit growth and strengthening Ligand’s position as a leading biopharma royalty aggregator. Published April 27, 2026. Accessed April 28, 2026. https://investor.ligand.com/news-and-events/press-releases/news-details/2026/Ligand-to-Acquire-XOMA-Royalty-Further-Accelerating-Profit-Growth-and-Strengthening-Ligands-Position-as-a-Leading-Biopharma-Royalty-Aggregator/default.aspx
2. Shuster Jr. GW, Moore NJ. Royalty financings and similar revenue monetizations surge in difficult life sciences fundraising environment. WilmerHale. Sept. 5, 2024. Accessed April 28, 2026. https://www.wilmerhale.com/en/insights/client-alerts/20240904-royalty-financings-and-similar-revenue-monetizations-surge-in-difficult-life-sciences-fundraising-environment
3. Fleming C, Levin G, Rahmani F. Alternative sources of capital for biotechs. Sidley. Accessed April 28, 2026. https://trendspotting.sidley.com/trends/sources-of-capital
4. Cleary’s Pharma Bites: Contingent value rights (CVRs) in pharmaceutical deals. Cleary Gottlieb Pharmaceutical. May 2024. Accessed April 28, 2026. https://www.clearygottlieb.com/-/media/files/clearys-pharma-bites/clearys-pharma-bites-contingent-value-rights-in-pharma-deals.pdf